First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls

Diagnostics, Journal Year: 2025, Volume and Issue: 15(2), P. 218 - 218

Published: Jan. 19, 2025

Background/Objectives: Over the past four years, 68Ga-fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) has been established at a tertiary cancer care facility in Jordan. This retrospective study aims to explore tracer uptake metrics across various epithelial neoplasms, identify diagnostic pitfalls associated with 68Ga-FAPI PET/CT, and evaluate influence of PET/CT staging results on changes therapeutic intent compared gold standard molecular imaging modalities. Methods: A total 48 patients biopsy-confirmed solid tumors underwent 77 examinations for assessment, encompassing neoplasms originating from gastrointestinal tract, head neck, hepatobiliary system, pancreas, breast, lung. Results: Notably, pancreaticobiliary exhibited highest uptake, mean maximum standardized values (SUVmax) tumor-to-background ratios (TBR) surpassing 10. comparative sub-analysis PET 20 treatment-naïve revealed significant correlation between tumor grade (Spearman’s rho 0.83; p = 0.00001). Importantly, influenced treatment decisions 35.5% cases, primarily resulting an escalation management plans. 220 challenges were identified 88.3% scans, predominantly within musculoskeletal attributed degenerative (99 observations). Conclusions: comprehensive analysis highlights potential significance oncological strategy, while also emphasizing necessity meticulous interpretation mitigate challenges.

Language: Английский

Enhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68Ga-FAPI PET/CT Compared to 18F-FDG PET/CT: A Case Report

World Journal of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid that arises from the lining abdominal cavity. While applications traditional fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in diagnosis staging DMPM are well-established, utility gallium-68 fibroblast activating protein inhibitor (68Ga-FAPI) PET/CT detecting disease recurrence remains an area requires further research validation, with limited literature. Implementing FAPI for these cases may provide superior lesion detectability higher reporter confidence, prompting need studies to investigate potential future role theranostics guiding treatment decisions DMPM. This case report describes 49-year-old male patient diagnosed DMPM, who underwent cytoreductive surgery hyperthermic intraperitoneal chemotherapy but developed recurrent was better visualized on 68Ga-FAPI compared 18F-FDG PET/CT.

Language: Английский